Not yet recruitingInterventionalPhase 2Last updated Aug 11, 2026

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

A Phase II Clinical Study of SSGJ-612 in Combination With a Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Antibody-Drug Conjugate (ADC) in Patients With Hormone Receptor (HR)-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Overview

ClinicalTrials.gov ID: NCT07757230
Lead Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY
Brief Summary: This study is a phase II clinical trial of SSGJ-612 combined with a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) in patients with hormone receptor (HR)-positive, HER2-low or HER2-ultralow metastatic breast cancer.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Sep 2026Estimated
Primary Completion Date: Feb 2028Estimated
Completion Date: Jul 2029Estimated

Study Record Dates

First Submitted: Aug 6, 2026
First Submitted that Met QC Criteria: Aug 6, 2026
First Posted: Aug 11, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 6, 2026
Last Update Posted: Aug 11, 2026Actual
Last Verified: Aug 2026

NCT07022002Recruiting

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

NCT07646626Recruiting

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

NCT07032298Recruiting

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

NCT05145179Unknown status

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

NCT07171606Recruiting

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

NCT06412471Unknown status

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients